Remember meForgot password?
    Log in with Twitter
Press Release

Calgary Canada Class Action Xarelto Lawsuit Filed As Another Class Action Suit Is Likely Forming In Ontario reports on an article recently published in the Calgary Sun discussing the a class action lawsuit which was filed against Bayer Inc., one manufacturer of the new-generation, blood-thinning drug Xarelto in Calgary, Canada. According to the head plaintiff in this Canadian class action lawsuit, the drug caused her to suffer from an uncontrollable bleeding episode which allegedly almost led to cardiac arrest.

This Canadian class action lawsuit closely follows the formation of Multidistrict Litigation number 2592 in the United States, which involves a group of more than 2,800 lawsuits filed against Xarelto. This MDL was formed by the U.S. Judicial Panel on Multidistrict Litigation. In addition to this group of Xarelto lawsuits in the United States, another group of more than 600 cases has formed a mass tort program in Philadelphia, Pennsylvania, created by the Court of Common Pleas. These lawsuits were filed against Bayer as well as Johnson & Johnson subsidiary, Janssen Pharmaceuticals.

According to the Calgary Sun, it was reported that as of March 2015, Health Canada had received around 1,100 reports detailing adverse events experienced by patients using Xarelto. The article notes that, according to a Toronto lawyer, if the class action is successful, “ would be in the millions of dollars.” The article notes that another class action suit may be forming in Ontario as well.

In the United States, Xarelto gained FDA approval in 2011 to treat patients with pulmonary embolism, deep vein thrombosis, and atrial fibrillation, as well as those recovering from hip and knee replacement surgeries. The drug was initially popular, launching onto the market as a revolutionary blood thinner that provided patients with more freedoms than traditional blood thinners had in the past. Since this time, however, Xarelto has become the subject of increasing controversies and is regarded by many as one of the most dangerous blood thinners on the market. The FDA has given the product two “black box” warnings, which are the most severe warnings a product can receive before being completely pulled from the market.

Commonly reported side effects that have been attributed to the drug by those filing suits are pulmonary embolisms (blood clots in the lung), rectal bleeding, heart attack, stroke, epidural hematoma, internal bleeding, gastrointestinal bleeding and brain hemorrhages.

As thousands of Xarelto lawsuit plaintiffs await trial, those involved expect that lawsuit numbers surrounding the anticoagulant drug will only continue to rise. As this continues, Attorney Joseph Osborne is working to help ensure that patients who believe they have suffered from adverse health events due to their use of Xarelto will be given the opportunity to fully evaluate their legal rights in the matter. These patients may be entitled to significant compensation attained through legal action. To better assist those affected, Attorney Osborne is offering complimentary legal consultations for qualified parties at this time.

To request additional information concerning Xarelto lawsuits, or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.



Joseph Osborne
Mizner Park 433 Plaza Real Blvd., Ste. 271 Boca Raton, FL 33432

Latest News
Top News